~~<i id='98F647111C'><strike id='98F647111C'><tt id='98F647111C'><pre id='98F647111C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：entertainment 2025-09-29 20:52:35 - browse：958

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Deliver public health messages at the right time

hotspot

Wikipedia

leisure time

focus

leisure time

1:10Asthetemperatureclimbs,sodoesthedangerforchildrenleftinhotvehicles.STOCKPHOTO/GettyImagesAFlorid

WSS

What is artificial intelligence? Experts weigh in

As billionaires fund anti

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Biden White House, tech companies launch new safeguards around emerging AI technology

What is the Turing Test that determines if computers can think?

A new deal aims to ramp up use of AI in rehab care decisions

focus

comprehensive

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

GSK’s asthma push continues as drug succeeds in Phase 3 trials

ChatGPT in medicine: STAT answers readers' burning questions

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Medicare details structure of new drug price negotiation program

AltruBio raises $225 million to develop ulcerative colitis drug

United colonoscopy coverage change 'may cost lives,' doctors say

Biden White House, tech companies launch new safeguards around emerging AI technology

Trump demands the U.S. pay no more for drugs than other countries … again

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Wikipedia

EMA weighs against approval for Mirati's lung cancer drug

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Why Marc Tessier

GSK’s asthma push continues as drug succeeds in Phase 3 trials

The effects of a landmark ruling on DNA ownership are becoming clearer

A new deal aims to ramp up use of AI in rehab care decisions

leisure time

focus

focus

leisure time